/ADAG
ADAG Stock - Adagene Inc.
Healthcare|BiotechnologyNASDAQ
$1.82-0.55%
$0.01 (-0.55%) • Dec 19
75
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.46
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.91
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+174.7%upside
Target: $5.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ADAG
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.80 – $1.84
TARGET (TP)$5.00
STOP LOSS$1.67
RISK/REWARD1:21.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.71
52W High$3.16
52W Low$1.30
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $103,204 | $18.11M | $9.29M | $10.18M | $480,000 |
| Gross Profit | $-823,044 | $18.11M | $9.29M | $10.18M | $480,000 |
| Gross Margin | -797.5% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-35,951,543 | $-23,719,866 | $-83,920,683 | $-72,364,089 | $-19,169,650 |
| Net Income | $-33,424,111 | $-18,946,370 | $-79,971,847 | $-73,177,935 | $-16,435,472 |
| Net Margin | -32386.4% | -104.6% | -860.6% | -719.2% | -3424.1% |
| EPS | $-0.95 | $-0.55 | $-2.31 | $-2.29 | $-0.59 |
Company Overview
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
67%
Hold / Neutral
1
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
2 Bullish1 Neutral/Bearish
Price Targets
$8
Average Target
↑ 339.6% Upside
Now
$7
Low
$8
Average
$9
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 24th 2025 | Guggenheim | Initiation | Buy | $9 |
| August 6th 2025 | Leerink Partners | Initiation | Outperform | $7 |
| January 31st 2025 | Morgan Stanley | Downgrade | Equal Weight | - |
Earnings History & Surprises
ADAGBeat Rate
43%
Last 7 quarters
Avg Surprise
-55.0%
EPS vs Estimate
Beats / Misses
3/4
Last 12 quarters
Latest EPS
$-0.55
Q1 2025
EPS Surprise History
Q1 23
-287.5%
$-1.55vs$-0.40
Q1 23
No data
Q3 23
+87.6%
$-0.05vs$-0.38
Q3 23
No data
Q1 24
+59.8%
$-0.17vs$-0.42
Q1 24
No data
Q3 24
+53.0%
$-0.19vs$-0.41
Q1 25
-67.7%
$-0.55vs$-0.33
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 23, 2026 | — | — | — | — |
Q1 2025 | Mar 24, 2025 | $-0.33 | $-0.55 | -67.7% | ✗ MISS |
Q3 2024 | Jul 25, 2024 | $-0.41 | $-0.19 | +53.0% | ✓ BEAT |
Q1 2024 | Mar 31, 2024 | — | $-0.19 | — | — |
Q1 2024 | Mar 29, 2024 | $-0.42 | $-0.17 | +59.8% | ✓ BEAT |
Q3 2023 | Sep 30, 2023 | — | $-0.17 | — | — |
Q3 2023 | Aug 31, 2023 | $-0.38 | $-0.05 | +87.6% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | — | $-0.05 | — | — |
Q1 2023 | Mar 28, 2023 | $-0.40 | $-1.55 | -287.5% | ✗ MISS |
Q3 2022 | Sep 30, 2022 | — | $-0.38 | — | — |
Q3 2022 | Aug 30, 2022 | $-0.65 | $-1.09 | -68.0% | ✗ MISS |
Q3 2021 | Sep 30, 2021 | — | $-0.41 | — | — |
Q3 2021 | Aug 26, 2021 | $-0.39 | $-1.02 | -161.9% | ✗ MISS |
Q3 2020 | Sep 30, 2020 | — | $-0.33 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.72 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-0.72 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.15 | — | — |
Q3 2019 | Sep 30, 2019 | — | $-0.39 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.30 | — | — |
Q1 2019 | Mar 31, 2019 | — | $-0.30 | — | — |
Latest News
Adagene, Palvella gain after FDA Fast Track Designations
📈 PositiveSeeking Alpha•Dec 16, 2025, 02:24 PM•Also:
The FDA Has Designated Adagene's Muzastotug, In Combination With Merck's Keytruda (Pembrolizumab), As A Fast Track Product For Adult Patients With Microsatellite Stable Metastatic Colorectal Cancer Without Current Or Active Liver Metastases
📈 PositiveBenzinga•Dec 16, 2025, 12:06 PM•Also:
Guggenheim Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9
📈 PositiveBenzinga•Nov 24, 2025, 01:30 PM
Adagene And Third Arc Bio Enter Agreement Advancing SAFEbody Powered CD3 T Cell Engagers With Up To $845M In Total Value
📈 PositiveBenzinga•Nov 13, 2025, 12:12 PM
Adagene Says First Patient Dosed In Randomized, Open Label Phase 2 Study Of Muzastotug In Combination With Merck's Anti-PD-1 Therapy, KEYTRUDA In Patients With MSS CRC With No Liver Metastases
📈 PositiveBenzinga•Oct 31, 2025, 11:02 AM•Also:
LUCID CAPITAL MARKETS Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9
📈 PositiveBenzinga•Sep 18, 2025, 12:21 PM•Also:
Adagene Expands Announces Amendment Ti 2021 Collaboration And License Agreement With Exelixis, Under Which Exelixis Will Utilize Adagene's SAFEbody Platform To Generate A Masked Antibody-Drug Conjugate
📈 PositiveBenzinga•Sep 16, 2025, 12:07 PM•Also:
Adagene shares are trading higher after the company announced that ADG126 will be highlighted in two oral presentations at this year's CSCO Meeting.
📈 PositiveBenzinga•Sep 5, 2025, 03:55 PM•Also:
Adagene's Masked CTLA-4 Antibody ADG126 To Be Highlighted In Dual Oral Presentations At 2025 CSCO Meeting; Data Highlights Include Phase 1b/2 Results In MSS CRC And Combination With Pembrolizumab
📈 PositiveBenzinga•Sep 5, 2025, 02:01 PM•Also:
Adagene gains as Sanofi collaboration expands
📈 PositiveSeeking Alpha•Jul 1, 2025, 11:31 AM•Also:
Frequently Asked Questions about ADAG
What is ADAG's current stock price?
Adagene Inc. (ADAG) is currently trading at $1.82 per share. The stock has moved -0.55% today.
What is the analyst price target for ADAG?
The average analyst price target for ADAG is $5.00, based on 1 analyst.
What sector is Adagene Inc. in?
Adagene Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ADAG's market cap?
Adagene Inc. has a market capitalization of $0.07 billion, making it a small-cap company.
Does ADAG pay dividends?
No, Adagene Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACET
Adicet Bio, Inc.
$0.49
Mkt Cap: $0.0B
CRVO
CervoMed Inc.
$7.60
Mkt Cap: $0.1B
FBIO
Fortress Biotech, Inc.
$3.54
Mkt Cap: $0.1B
GANX
Gain Therapeutics, Inc.
$2.88
Mkt Cap: $0.1B
LITS
Lite Strategy, Inc.
$1.43
Mkt Cap: $0.1B
NRXP
NRx Pharmaceuticals, Inc.
$2.37
Mkt Cap: $0.0B
NTRB
Nutriband Inc.
$4.49
Mkt Cap: $0.1B
OSTX
OS Therapies Incorporated
$1.54
Mkt Cap: $0.1B
TCRX
TScan Therapeutics, Inc.
$0.90
Mkt Cap: $0.1B
XBIT
XBiotech Inc.
$2.50
Mkt Cap: $0.1B
Explore stocks similar to ADAG for comparison